CQP: The clinical trial for hydrochloride prasugrel tablets has been approved
I'm PortAI, I can summarize articles.
CQP announced that its holding subsidiary Chongqing Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for Prasugrel Hydrochloride Tablets. This medication is used to prevent cardiovascular diseases such as acute coronary syndrome and is currently marketed in over 70 countries worldwide, but has not yet been launched in China
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments